ProPhase Labs Inc (NASDAQ:PRPH) Sees Significant Decrease in Short Interest
ProPhase Labs Inc (NASDAQ:PRPH) was the recipient of a significant decline in short interest in July. As of July 31st, there was short interest totalling 4,400 shares, a decline of 42.1% from the June 30th total of 7,600 shares. Currently, 0.1% of the shares of the stock are short sold. Based on an average trading volume of 10,500 shares, the days-to-cover ratio is currently 0.4 days.
An institutional investor recently bought a new position in ProPhase Labs stock. Dimensional Fund Advisors LP purchased a new position in shares of ProPhase Labs Inc (NASDAQ:PRPH) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 10,817 shares of the company’s stock, valued at approximately $34,000. Dimensional Fund Advisors LP owned about 0.09% of ProPhase Labs at the end of the most recent quarter. Hedge funds and other institutional investors own 4.32% of the company’s stock.
NASDAQ PRPH traded up $0.01 during trading on Wednesday, hitting $2.01. 12,304 shares of the company’s stock were exchanged, compared to its average volume of 8,638. ProPhase Labs has a fifty-two week low of $1.97 and a fifty-two week high of $4.00. The firm’s 50 day moving average price is $2.08.
Separately, TheStreet downgraded ProPhase Labs from a “c-” rating to a “d+” rating in a research note on Tuesday, July 9th.
ProPhase Labs Company Profile
ProPhase Labs, Inc engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter(OTC) consumer healthcare products, dietary supplements, and other remedies in the United States. The company offers TK Supplements product line include Legendz XL for sexual health; Triple Edge XL, an energy booster and testosterone support; and Super ProstaFlow+ for prostate and urinary health.
Featured Story: How Investors Can Profit from Options Trading
Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.